Impact of Fetuin-A (AHSG) on Tumor Progression and Type 2 Diabetes

• Published in: International journal of molecular sciences 2018-07, Vol.19 (8), p.2211
• Main Authors: Ochieng, Josiah, Nangami, Gladys, Sakwe, Amos, Moye, Cierra, Alvarez, Joel, Whalen, Diva, Thomas, Portia, Lammers, Philip
• Format: Article
• Language: English
• Subjects: alpha-2-HS-Glycoprotein - analysis; alpha-2-HS-Glycoprotein - metabolism; Animals; Apoptosis; attachment; Autoantibodies; Blood levels; Calcification; Calcification (ectopic); Cancer; Cell Movement; Cell Proliferation; Complications; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - metabolism; Diabetes Mellitus, Type 2 - pathology; Disease Progression; exosomes; fetuin-A; Glioblastoma; growth; Humans; Insulin; Insulin resistance; Liver; Neoplasm Invasiveness - pathology; Neoplasms - metabolism; Neoplasms - pathology; Pancreas; Pancreas - metabolism; Pancreas - pathology; Prostate; Proteins; Receptor, Insulin - metabolism; Review; Secretion; tumor; Tumor cells; Tumor Microenvironment; Tumors
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms19082211

Fetuin-A is the protein product of the gene in humans. It is mainly synthesized by the liver in adult humans and is secreted into the blood where its concentration can vary from a low of ~0.2 mg/mL to a high of ~0.8 mg/mL. Presently, it is considered to be a multifunctional protein that plays important roles in diabetes, kidney disease, and cancer, as well as in inhibition of ectopic calcification. In this review we have focused on work that has been done regarding its potential role(s) in tumor progression and sequelae of diabetes. Recently a number of laboratories have demonstrated that a subset of tumor cells such as pancreatic, prostate and glioblastoma multiform synthesize ectopic fetuin-A, which drives their progression. Fetuin-A that is synthesized, modified, and secreted by tumor cells may be more relevant in understanding the pathophysiological role of this enigmatic protein in tumors, as opposed to the relatively high serum concentrations of the liver derived protein. Lastly, auto-antibodies to fetuin-A frequently appear in the sera of tumor patients that could be useful as biomarkers for early diagnosis. In diabetes, solid experimental evidence shows that fetuin-A binds the β-subunit of the insulin receptor to attenuate insulin signaling, thereby contributing to insulin resistance in type 2 diabetes mellitus (T2DM). Fetuin-A also may, together with free fatty acids, induce apoptotic signals in the beta islets cells of the pancreas, reducing the secretion of insulin and further exacerbating T2DM.